Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 19/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680981 | 1.00 | CETP (0.40) | CETPCYP3A4TACR1 | |
| SCHEMBL680609 | 0.96 | CETP (0.42) | CETPCYP3A4TACR1 | |
| SCHEMBL13118711 | 0.96 | CETP (0.42) | CETPCYP3A4TACR1 | |
| SCHEMBL680610 | 0.96 | CETP (0.42) | CETPCYP3A4TACR1 | |
| Hydrochloric Acid SCHEMBL680533 | 0.96 | CETP (0.41) | CETPCYP3A4TACR1 | |
| Hydrochloric Acid SCHEMBL680534 | 0.96 | CETP (0.41) | CETPCYP3A4TACR1 | |
| SCHEMBL680809 | 0.94 | CETP (0.42) | CETP | |
| SCHEMBL680808 | 0.94 | CETP (0.42) | CETP | |
| Hydrochloric Acid SCHEMBL680399 | 0.94 | CETP (0.42) | CETP | |
| Hydrochloric Acid SCHEMBL680398 | 0.94 | CETP (0.42) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | claimed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | claimed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | claimed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | claimed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | claimed |
| US-9724362-B2 | Pharmaceutical compositions comprising nanoparticles and a resuspending material | BEND RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9545384-B2 | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate | BEND RESEARCH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2162120-B1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2231169-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-8974827-B2 | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer | BEND RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | TACR1 1017/4885CETP 1/4885CYP3A4 448/4885 |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | TACR1 803/4885CETP 1/4885CYP3A4 356/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | TACR1 1329/4885CETP 1/4885CYP3A4 1980/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | TACR1 1329/4885CETP 1/4885CYP3A4 1980/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | TACR1 656/4885CETP 1/4885CYP3A4 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.